Primary study · included by 1 review
Impact of Androgen Suppression Therapy on the Risk and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis.
Xiang 2021 · Xiang Peng, Du Zhen, Hao Yongxiu, et al. · Frontiers in oncology · 2021
Included by
| Outcome this study informs | Pooled effect | Evidence | Certainty |
|---|---|---|---|
Risk of bladder cancer Use of thiazolidinediones vs No use | RR 1.13 [1.05, 1.23] | 7 studies · 2161655 participants | Very low |
Risk of bladder cancer Androgen deprivation therapy vs No androgen suppression therapy | OR 1.00 [0.46, 2.15] | 4 studies · 242845 participants | Very low |
Risk of bladder cancer Use of thiazolidinediones: rosiglitazone vs No use | RR 1.08 [0.95, 1.23] | 3 studies · 1508042 participants | Very low |
Risk of bladder cancer With 5-alpha reductase inhibitors vs Without 5-alpha reductase inhibitors | OR 0.75 [0.64, 0.88] | 4 studies · 180829 participants | Low |
Risk of bladder cancer Androgen suppression therapy (total) vs No androgen suppression therapy | OR 0.92 [0.68, 1.24] | 8 studies · 423674 participants | Very low |
1 including review in total.